These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37387459)

  • 21. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous quantification of tau and α-synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls.
    Viodé A; Epelbaum S; Benyounes I; Verny M; Dubois B; Junot C; Fenaille F; Lamari F; Becher F
    Analyst; 2019 Oct; 144(21):6342-6351. PubMed ID: 31553333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
    Bousiges O; Bombois S; Schraen S; Wallon D; Quillard MM; Gabelle A; Lehmann S; Paquet C; Amar-Bouaziz E; Magnin E; Miguet-Alfonsi C; Delbeuck X; Lavaux T; Anthony P; Philippi N; Blanc F;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):467-475. PubMed ID: 29321140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical Practice.
    Lilamand M; Clery J; Vrillon A; Mouton-Liger F; Cognat E; Gaubert S; Hourregue C; Martinet M; Dumurgier J; Hugon J; Bouaziz-Amar E; Paquet C
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People.
    de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
    J Alzheimers Dis; 2021; 81(3):1295-1309. PubMed ID: 33935098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
    Schaeffer MJ; Callahan BL;
    J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration.
    Chai YL; Chong JR; Weng J; Howlett D; Halsey A; Lee JH; Attems J; Aarsland D; Francis PT; Chen CP; Lai MKP
    Brain Pathol; 2019 Jan; 29(1):63-74. PubMed ID: 30051532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies.
    van de Beek M; Babapour Mofrad R; van Steenoven I; Vanderstichele H; Scheltens P; Teunissen CE; Lemstra AW; van der Flier WM
    Alzheimers Res Ther; 2020 Apr; 12(1):44. PubMed ID: 32303272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?
    Jellinger KA
    Parkinsonism Relat Disord; 2022 Jul; 100():24-32. PubMed ID: 35691178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    Jellinger KA; Korczyn AD
    BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies.
    Kasanuki K; Iseki E; Fujishiro H; Yamamoto R; Higashi S; Minegishi M; Togo T; Katsuse O; Uchikado H; Furukawa Y; Hino H; Kosaka K; Sato K; Arai H
    J Neurol Sci; 2012 Mar; 314(1-2):111-9. PubMed ID: 22041339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies.
    Foska A; Tsantzali I; Sideri E; Stefanou MI; Bakola E; Kitsos DK; Zompola C; Bonakis A; Giannopoulos S; Voumvourakis KI; Tsivgoulis G; Paraskevas GP
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design.
    Toledo JB; Abdelnour C; Weil RS; Ferreira D; Rodriguez-Porcel F; Pilotto A; Wyman-Chick KA; Grothe MJ; Kane JPM; Taylor A; Rongve A; Scholz S; Leverenz JB; Boeve BF; Aarsland D; McKeith IG; Lewis S; Leroi I; Taylor JP;
    Alzheimers Dement; 2023 Jan; 19(1):318-332. PubMed ID: 36239924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load.
    Chong JR; Chai YL; Lee JH; Howlett D; Attems J; Ballard CG; Aarsland D; Francis PT; Chen CP; Lai MK
    J Alzheimers Dis; 2017; 56(1):157-166. PubMed ID: 27911312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects.
    Blanc F; Bousiges O
    Rev Neurol (Paris); 2022 May; 178(5):472-483. PubMed ID: 35491246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B; Bibl M; Wiltfang J; Steinacker P; Ciesielczyk B; Neubert K; Trenkwalder C; Otto M
    Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.